November 27, 2013
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

EnglishTranslation

SymBio Announces Pricing of Secondary Offering and Overallotment
TOKYO, Japan, November 27, 2013 -- SymBio Pharmaceuticals Limited (JASDAQ: 4582, hereinafterreferred to as “the Company”) announced today it has determined the issue price, the selling price and othermatters in relation to the issuance of new shares and the secondary offering of shares of the Company,
which were resolved at the Company’s Board of Directors Meeting held on November 19, 2013.
The details of these determinations are as stated below.

1. Summary of Fund Raising(1) New share issue through the public offering(1) Issue Price

400 JPY per share(2) Total Amount of Issue Price

2,688,080,000JPY(3) Amount to be paid

372.57JPY per share(4) Total amount to be paid

2,503,744,914JPY(5) Amount of capital and paid-in
capital to be increased

Capital increase
Additional paid-in capital increase(6) Subscription Period

From Thursday, November 28, 2013 to Friday, November 29,2013(7) Payment Date

Wednesday, December 4, 2013(8) Delivery Date

Thursday, December 5, 2013(9) Others

SMBC Nikko Securities Inc. will underwrite and purchase at theamount to be paid and offer at the issue price (offer price).

:1,251,872,457 JPY:1,251,872,457 JPY(2) Secondary Offering (Over-allotments)(1) Number of shares of secondaryoffering

1,008,000 shares(2) Secondary offering price400JPY per share(3) Total amount of the secondaryoffering price403,200,000JPY(4) Subscription Period

From Thursday, November 28, 2013 to Friday, November 29,2013(5) Delivery Date

Thursday, December 5, 2013

-1-

Note: This press release has been prepared for the sole purpose of publicly announcing certain matters relating to theOffering of shares of the Company and not for the purpose of soliciting investment or engaging in any othersimilar activity. This press release does not constitute an offer of any securities for sale within or outside Japan.
Additionally, this press release is not an offer of securities for sale in the United States. The securities have notand will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not beoffered or sold in the United States absent registration or an exemption from registration under the Securities Act.
No offering of securities in the United States will be made in connection with the above mentioned transactions.

(3) Issuance of new shares by way of third party allotment(1) Amount to be paid

372.57JPY per share(2) Total amount to be paid

Maximum 375,550,560JPY(3) Amount of capital and paid-in
capital to be increased

Capital increase
Additional paid-in capital increase(4)Subscription Period

Tuesday, December 24, 2013(5) Payment Date

Wednesday, December 25, 2013

: 187,775,280JPY: 187,775,280JPY

2. Calculation of Issue price and Secondary offering price(1) Base Date for calculation and price per share on the Base Date:
Wednesday, November 27, 2013,422JPY(2) Discount Rate : 5.21%

3. Syndicate covering transaction period:
From Saturday, November 30, 2013 to Thursday, December 19, 2013

4. Use of Funds RaisedThis fund will be allocated during a period from January, 2014 through December, 2015 toward
development expenses for SyB L-1101 (rigosertib, intravenous) for treating relapsed and refractoryMyelodysplastic Syndromes (MDS) and SyB C-1101 (rigosertib, oral agent) for the initial treatment ofMDS. Proceeds will also be used to fund development and milestone payments for SyB
L/C-1101(rigosertib, intravenous and oral agent) in additional indications outside of MDS.
Until specific financial needs arise, it is our policy to manage this fund by, among other methods,
investing it in low risk financial instruments.
About Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes represent a group of diverse myeloid (bone marrow) stem cell disorders that
gradually affect the ability of bone marrow to produce red blood cells, white blood cells and platelets
sufficiently. Blood stem cells fail to mature into healthy blood cells, and the immature blood cells, called
blasts, do not function normally and either die in the bone marrow or enter the blood. A higher percent ofblasts is linked to a higher likelihood of developing acute myeloid leukemia and poorer overall prognosis.
The risk of MDS increases with age and the disease commonly affects the elderly. In Japan, the number ofthe patients is estimated to be around 11,000 (according to the survey of patients by the Ministry of Health,Labour and Welfare in 2011). At present, there is only one therapeutic agent sold as a treatment for MDS,and therefore the patients are waiting for a new medical agent for the disease to be developed.

-2-Note: This press release has been prepared for the sole purpose of publicly announcing certain matters relating to theOffering of shares of the Company and not for the purpose of soliciting investment or engaging in any othersimilar activity. This press release does not constitute an offer of any securities for sale within or outside Japan.
Additionally, this press release is not an offer of securities for sale in the United States. The securities have notand will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not beoffered or sold in the United States absent registration or an exemption from registration under the Securities Act.
No offering of securities in the United States will be made in connection with the above mentioned transactions.

About SymBio Pharmaceuticals LimitedSymBio Pharmaceuticals was established in March, 2005, by Fuminori Yoshida, who previously served
concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan (currently Takeda Bio
Development Center Limited). The company’s underlying corporate mission is “delivering hope to patients inneed” as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated toaddressing underserved medical needs with focus in oncology, hematology and autoimmune disease.

[Contact]
Tomoyuki Watanabe
Director, Head of Corporate Planning Division
Tel: +081(0)3 5472 1125-3-Note: This press release has been prepared for the sole purpose of publicly announcing certain matters relating to theOffering of shares of the Company and not for the purpose of soliciting investment or engaging in any othersimilar activity. This press release does not constitute an offer of any securities for sale within or outside Japan.
Additionally, this press release is not an offer of securities for sale in the United States. The securities have notand will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be
offered or sold in the United States absent registration or an exemption from registration under the Securities Act.
No offering of securities in the United States will be made in connection with the above mentioned transactions.